Skip to main content

Enasidenib Side Effects

Medically reviewed by Last updated on Aug 21, 2023.

Applies to enasidenib: oral tablet.


Oral route (Tablet)

Patients treated with enasidenib have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.Early recognition and aggressive management of differentiation syndrome is required to lessen the likelihood of serious illness and death. Symptoms of differentiation syndrome should be described to patients when starting therapy and at follow-up visits. Differentiation syndrome has occurred as early as 10 days and up to 5 months after initiating therapy.

Serious side effects of Enasidenib

Along with its needed effects, enasidenib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking enasidenib:

More common

Other side effects of Enasidenib

Some side effects of enasidenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to enasidenib: oral tablet.


The most common (30% or more) adverse reactions of any grade were elevated bilirubin, decreased calcium and potassium levels, nausea, diarrhea, vomiting, and decreased appetite.[Ref]


Very common (10% or more): Increased total bilirubin (81%)[Ref]


Very common (10% or more): Decreased calcium (74%), decreased potassium (41%), decreased appetite (34%), decreased phosphorus (27%)

Common (1% to 10%): Tumor lysis syndrome, decreased weight[Ref]


Very common (10% or more): Nausea (50%), diarrhea (43%), vomiting (34%)

Common (1% to 10%): Abdominal pain[Ref]


Very common (10% or more): Differentiation syndrome (14%), noninfectious leukocytosis (12%)[Ref]

Nervous system

Very common (10% or more): Dysgeusia (12%)[Ref]


Common (1% to 10%): Rash[Ref]


Common (1% to 10%): Increased uric acid[Ref]


Common (1% to 10%): Pyrexia, peripheral edema[Ref]


Common (1% to 10%): Renal insufficiency[Ref]


Common (1% to 10%): Respiratory failure, dyspnea, hypoxia, pulmonary edema, acute respiratory distress syndrome[Ref]

Frequently asked questions


1. (2017) "Product Information. Idhifa (enasidenib)." Celgene Corporation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.